Relief Therapeutics Holding SA (LON: 0QKQ)
London
· Delayed Price · Currency is GBP · Price in CHF
3.720
+0.130 (3.62%)
Jan 23, 2025, 12:03 PM BST
Relief Therapeutics Holding Revenue
Relief Therapeutics Holding had revenue of 3.01M CHF in the half year ending December 31, 2023, a decrease of -9.36%. This brings the company's revenue in the last twelve months to 8.60M, up 45.04% year-over-year. In the year 2023, Relief Therapeutics Holding had annual revenue of 6.03M, down -0.79%.
Revenue (ttm)
8.60M CHF
Revenue Growth
+45.04%
P/S Ratio
n/a
Revenue / Employee
175.47K CHF
Employees
49
Market Cap
39.38M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Relief Therapeutics Holding News
- 27 days ago - Relief Therapeutics advances merger talks with Renexxion - Seeking Alpha
- 27 days ago - Relief Therapeutics Provides Update on Potential Transaction with Renexxion - Accesswire
- 5 weeks ago - Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial - Accesswire
- 5 weeks ago - Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations - Accesswire
- 2 months ago - Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa - Accesswire
- 2 months ago - Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger - Accesswire
- 3 months ago - Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment - Accesswire
- 4 months ago - Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 - Accesswire